

Market Launches of New Molecular Entities in Germany 2009

Number (excluding biosimilars)



Source: Pharmazeutische Zeitung, vfa

37 pharmaceuticals based on new NMEs (new substances known internationally as New Molecular Entities) were launched in the German market in 2009 – the highest number since 1997. Because of the global research process, the number of such substances launched in Germany is closely connected to the international development of pharmaceuticals. Unless they are of merely regional importance, most new NMEs receive marketing authorization as soon as possible in all key countries. This is the only way to balance the costs for research and development of an NME, which globally amount to USD 800 million on average, within its limited patent term.